NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer | Journal for ImmunoTherapy of Cancer
Pegging The Value Of NKTR-214 At Zero (NASDAQ:NKTR) | Seeking Alpha
Nektar | Pipeline | Winter Congress Virtual Booth
Single-agent efficacy of NKTR-214 compared with aldesleukin in... | Download Scientific Diagram
JCM | Free Full-Text | Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update | HTML
![PDF] PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ac84a0206049aa7de2ea3c0e7e3ec3f34d9e076f/1-Figure2-1.png "PDF] PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors. | Semantic Scholar")
PDF] PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors. | Semantic Scholar
Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy | PLOS ONE
Immuno-oncology: Nektar Therapeutics and Alkermes present data
Nektar Therapeutics: Encouraging Data Revealed At SITC (NASDAQ:NKTR) | Seeking Alpha
NKTR-214 delivers a controlled, sustained, and biased signal through... | Download Scientific Diagram
Parameterization of the mathematical model for NKTR-214 dynamics to... | Download Scientific Diagram
IsoPlexis' Blood-Based Biomarker Predicts Progression-Free Survival in Melanoma Study | IsoPlexis
ASCO 2019: Positive PIVOT-02 study of bempegaldesleukin with nivolumab
NKTR 214 | New Drug Approvals
Pegging The Value Of NKTR-214 At Zero (NASDAQ:NKTR) | Seeking Alpha
NKTR-214 synergizes with checkpoint blockade therapy a–c Mice bearing... | Download Scientific Diagram
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy | Nature Communications
JCM | Free Full-Text | Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update | HTML
Nektar submits IND for NKTR-214 to treat solid tumours
Nektar shows durability of Opdivo combo in 18-month update | Fierce Biotech
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy | Nature Communications
Bristol/Nektar's Opdivo/NKTR-214 Combo Responses Deepen Over Time
